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Introduction. Local microstructural pathology in multiple sclerosis patients might influence their clinical performance. This study
applied multicontrast MRI to quantify inflammation and neurodegeneration in MS lesions. We explored the impact of MRI-
based lesion pathology in cognition and disability.Methods. 36 relapsing-remitting MS subjects and 18 healthy controls underwent
neurological, cognitive, behavioural examinations and 3 T MRI including (i) fluid attenuated inversion recovery, double inversion
recovery, and magnetization-prepared gradient echo for lesion count; (ii) T1, T2, and T2∗ relaxometry and magnetisation transfer
imaging for lesion tissue characterization. Lesions were classified according to the extent of inflammation/neurodegeneration. A
generalized linear model assessed the contribution of lesion groups to clinical performances. Results. Four lesion groups were
identified and characterized by (1) absence of significant alterations, (2) prevalent inflammation, (3) concomitant inflammation
and microdegeneration, and (4) prevalent tissue loss. Groups 1, 3, 4 correlated with general disability (Adj-𝑅2 = 0.6; 𝑃 = 0.0005),
executive function (Adj-𝑅2 = 0.5; 𝑃 = 0.004), verbal memory (Adj-𝑅2 = 0.4; 𝑃 = 0.02), and attention (Adj-𝑅2 = 0.5; 𝑃 = 0.002).
Conclusion. Multicontrast MRI provides a new approach to infer in vivo histopathology of plaques. Our results support evidence
that neurodegeneration is the major determinant of patients’ disability and cognitive dysfunction.
1. Introduction
Multiple sclerosis (MS) is an inflammatory and neurode-
generative disease affecting the brain and spinal cord. The
hallmark of MS is the presence of multifocal lesions or
“plaques,” which are characterized by variable inflammatory,
degenerative, and reparative processes [1, 2]. Plaques inflam-
mation is widespread in the relapsing-remitting MS subtype,
whereas important tissue loss is pronounced in progressive
MS and in long-standing disease [3, 4]. In addition, new
lesions are mostly characterized by inflammatory phenom-
ena, leading to blood-brain barrier disruption, while older
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lesions show a higher proportion of neurodegeneration
and/or repair processes [4, 5].
Conventional magnetic resonance imaging (cMRI) is
a valuable tool to provide information about the num-
ber, location, and inflammatory “activity” of focal lesions.
Nevertheless cMRI offers only limited sensitivity to focal
pathology in the cortex and little insight into the nature
of local damage. Nonconventional MRI techniques such as
double inversion recovery (DIR, Geurts Radiology 2005) and
magnetization-prepared 2 rapid gradient echo (MP2RAGE,
Marques Neuroimage 2010 and Kober 2012) have proven
higher sensitivity to focal cortical pathology than cMRI. Sim-
ilarly, the combination of multiple cMRI contrasts improved
cortical lesions detection at all field strengths (1.5 T (B.
Moraal), 3 T (M. Archambault-Wallenburg), and 7 T (W. L.
De Graaf)). Besides, other advanced MRI techniques have
shown to be sensitive to tissue pathology in lesions, such
as axonal and myelin damage (diffusion tensor imaging
(DTI) andmagnetisation transfer imaging (MTI)) and axonal
metabolic deficits (magnetic resonance spectroscopy) [2, 6–
9]. MRI relaxometry has also been extensively used to study
normal-appearing brain tissue in multiple sclerosis patients
(for review see [9, 10]), but only few works focused on
lesions properties and heterogeneity [11, 12]. Yet, some recent
postmortem studies provided strong evidence of the value
of MRI relaxometry techniques to study specific aspects of
plaques pathology; Bagnato et al. showed that highR2∗ values
in the periphery of white matter (WM) lesions correlated
with iron accumulation in macrophages/microglia whereas
high R2∗ inside the WM plaque had the appearance of iron
aggregates typical of microbleeds [13]. Furthermore, Tardif
et al. established that myelin loss within cortical lesions
was associated with a concomitant increase of T1 and T2
relaxation times and a decrease of MTI measures [14].
In this work, we combined, in vivo in MS patients, three
relaxometry techniques (T1, T2, andT2∗), andMTI.The aims
of the study were (i) to classify MS cortical and white matter
lesions according to the extent of inflammatory and neu-
rodegenerative phenomena, as measured by unconventional
MRI and (ii) to assess the clinical impact of MRI measures of
lesion pathology in a cohort of relapsing-remitting multiple
sclerosis patients.
2. Methods
2.1. Study Population. Thirty-six patients with relapsing-
remitting MS (RRMS) and eighteen age-matched healthy
controls (HC) were enrolled in this cross-sectional study
between January and December 2012. The age of the patients
was 34.8 ± 9.2 years (mean ± standard deviation (SD)) and
gender ratio was 24/12, women/men. HC aged 33 ± 9.7 years
and had a gender ratio of 9/9. The time elapsed since the first
symptoms was 33.3 ± 21 months (range: 2–70 months) and
the time since disease diagnosis was 27.1 ± 18 months (range
0–59 months). Immunomodulatory treatment, consisting
in high dose interferon-beta (IFN-𝛽) or fingolimod, was
administered to thirty patients out of thirty-six patients (83%)
for at least 3 months. No patient had received corticosteroid
therapy within the three months preceding the study. The
study was approved by the ethics committee of the Lausanne
University Hospital (CHUV).Written, informed consent was
obtained from each subject.
2.2. Clinical Assessment. Verbal and spatial memory, sus-
tained attention, information processing speed, and verbal
fluency on semantic cues were assessed at the time ofMRI for
each subject using the Brief Repeatable Battery of Neuropsy-
chological Tests (BRB-N) [15]. Depression and fatigue were
quantified using the Hospital Anxiety and Depression Scale
(HAD) [16] and the Fatigue Scale for Motor and Cognitive
Functions (FSMC) [17]. Finally, the Expanded Disability
Status Scale (EDSS [18]) and theMultiple Sclerosis Functional
Composite (MSFC [19]) scores were evaluated to quantify
disability and motor performances.
2.3. MRI Acquisition. All subjects underwent MRI examina-
tions on a 3 T Siemens Trio (Siemens, Erlangen, Germany)
equipped with a 32-channel head coil. MRI protocol details
were previously reported in [20] and summarized in Table 1s
(supplementary data) (see Supplementary Material available
online at http://dx.doi.org/10.1155/2014/569123). In summary,
a 3D magnetization-prepared acquisition with gradient echo
(MPRAGE)was acquired for automatic brain tissue and atlas-
based segmentation [21–23]; 3D fluid attenuated inversion
recovery (3D FLAIR), 3D double inversion recovery (3D
DIR), and 3DMP2RAGE [11] were acquired for lesion detec-
tion and segmentation.TheMP2RAGE sequence additionally
provided whole-brain T1 relaxometry [24]. T2∗ relaxometry
maps were obtained using 32 echoes and a correctionmethod
based on an estimated B0 field map [25]. Magnetization
transfer ratio (MTR) maps were derived from the T2∗ data,
after registration of echoes with (MT) and without MT
pulse (M0) (MT pulse flip angle: 220∘; duration: 4000ms;
pulse offset: 2000Hz; and spoilermoment: 25000 us∗mT/m).
The magnetization transfer ratio MTR = (M0 − MT)/M0
was then computed for each echo and averaged over all
echoes. For T2 relaxometry, we used a new nonlinear inverse
reconstruction algorithm [26] that directly estimates a T2 and
spin-density map from a train of undersampled spin echoes.
The acquisition of T2 relaxometry maps was performed with
a spatial resolution, which is lower than the one achieved for
the other MRI contrasts and maps. Nevertheless, the current
protocol appears to have quite similar resolution compared
to recently published T2 mapping sequences [27] and was
optimized to achieve the best T2 maps quality in clinically
compatible scanning times.
Visual inspection of image quality was performed in all
cases. An example of T1, T2, and T2∗ and MTR maps is
reported in Figure 1.
The biological interpretation of changes in T1, T2, and
T2∗ relaxation times (rt) and MTR was summarized in
Figure 2 and previously reported in detail [20].
2.4. Image Analysis. Rigid registrations with BSpline inter-
polation were performed, using Elastix C++ [28], to register
(i) the T2 maps to the T1 maps (MP2RAGE) and (ii) the
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Figure 1: T1 map (a), MTR (b), T2 map (c), and T2∗ map (d) in one MS patient. An example of lesion is shown by a red arrow.
T2∗ maps, MPRAGE, FLAIR, and DIR images to one of the
inverted contrasts of the MP2RAGE sequence.
Cortical andWMMS lesions were manually identified in
patients by an experienced neurologist (CG) and a radiologist
(DR) using 3D FLAIR, 3D DIR, and MP2RAGE images,
as previously reported [20, 22, 24]. Manual contours were
generated for each lesion by a trained technician for each
contrast. As reported by [11, 20], we merged the lesions
extracted from FLAIR, DIR, and MP2RAGE to obtain a final
union lesion mask for each subject. Lesion volumes were
computed and normalized by total intracranial volume as
obtained using an in-house software [20, 29]. Only lesions
with more than 10 voxels size were included in the analysis.
Lesion masks were then registered to MP2RAGE space using
the registration parameters described above and mean T1,
T2∗ and MTR were calculated for each lesion.
In order to assess the mean distribution of T1, T2, and
T2∗ rt andMTR inHC brain tissue, we segmented lobarWM
and cortical GM (frontal, parietal, occipital, and temporal)
as well as cerebellar WM/GM from the MPRAGE images
using an in-house software based on variational expectation-
maximization tissue classification [20, 29].
To compare lesion MRI properties in patients with the
corresponding tissue in HC, we calculated a 𝑧-score for each
contrast in each lesion (e.g., for T1 data):
𝑧T1 =
1
𝑁
∑
V∈𝑙
𝐼T1 (V) − 𝜇T1 (𝐿 𝑙, 𝑇𝑙)
𝜎T1 (𝐿 𝑙, 𝑇𝑙)
, (1)
where 𝑧T1 corresponds to the T1 lesion 𝑧-score (𝑧), 𝑙 to the
lesion voxels, 𝑁 to a normalisation term, 𝐼T1 to the T1 map,
and 𝜇T1(𝐿 𝑙, 𝑇𝑙) and 𝜎T1(𝐿 𝑙, 𝑇𝑙) to the mean and the standard
deviation of the T1map in the lobe 𝐿
𝑙
and tissue 𝑇
𝑙
(i.e., WM
orGM) in theHC group, corresponding to the lesion location
and type.
Considering the continuous distribution (without dis-
tinct cluster) of lesions 𝑧-scores in each contrast, we classified
the lesions into 3 groups as follows: (i) 𝑧 very low (𝑧 < −2),
(ii) 𝑧 very high (𝑧 > 2), and (iii) 𝑧 close to theHCdistribution
(−2 ≤ 𝑧 ≤ 2). The thresholds were chosen considering
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Figure 2: Biological interpretation of quantitative and semiquantitative MRI contrasts.
the fact that more than 95 percent of the 𝑧-scores belong to
the interval [−2, 2] in a normal distribution and that values
beyond this interval reflect significant differences in patients
compared to controls (𝑃 < 0.05).
Last, for each subject, all existing combinations (Figure 3)
of 𝑧 were computed for all contrasts (e.g., combination 1 =
𝑧T1 > 2, 𝑧T2 > 2, 𝑧T2∗ > 2, and 𝑧MTR < −2; combination
2 = 𝑧T1 > 2, 𝑧T2 > 2, −2 < 𝑧T2∗ < 2, and 𝑧MTR <
−2, etc.) and mean lesion volume (MLV) was assessed for
each combination (total normalized lesion volume/number
of lesions).
2.5. Statistical Analysis
2.5.1. Between-Groups Comparisons of Subjects’ Demographics
and Clinical Scores. Differences in age, gender, education,
and clinical performance were assessed using a nonparamet-
ricANOVA(Kruskal-Wallis test) amongHCandMSpatients.
2.5.2. Multivariate Linear Regression of Clinical Scores in
Patients with T1, T2, T2∗ andMTR in Lesions. Amultivariate
linear regression of clinical scores was performed using
a general linear model (GLM) applied to MLV in each
combination of contrasts. Age, gender, educational years,
anxiety, and depression scores (HAD) were considered as
covariates, since they have been reported to be linked to
functional performance in MS patients [30, 31]. Cognitive
scores were adapted using Box-Cox transformation to satisfy
the model assumption for normality [32].
We performed eight regressions and applied a backward
stepwise approach to select the best predictionmodel for each
dependent variable (clinical scores). Bonferroni correction
was applied for multiple comparisons (seven tests). “Leave-
one-out” (LOO) cross-validation was applied to assess the
prediction quality and robustness of each model. A P value
< 0.05 was considered statistically significant.
All regression analyses were performed using R software
(http://www.R-project.org/).
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Figure 3: Groups and contrasts combinations of MS lesion 𝑧-
scores for T1, T2, and T2∗ and MTR contrasts, as observed in our
cohort of RRMS patients. Blue: parameter decrease; red: parameter
increase. Group 1: lesions with no significant q/sq MRI contrasts
changes; Group 2: lesions with prevalent inflammatory oedema;
Group 3: lesions with prevalent tissue degeneration with or without
inflammation; and Group 4: lesions with prevalent tissue loss.
3. Results
3.1. Between-Groups Comparisons of Subjects’ Demographics
and Clinical Scores. No significant differences were observed
between HC and MS patients in terms of age (𝑃 = 0.3) or
gender (𝑃 = 0.8); however, HC had slightly higher education
levels (17 ± 4 years, mean ± standard deviation) than MS
patients (15 ± 3 years; 𝑃 = 0.04).
Mean EDSS in patients was 1.6 ± 0.3 (interval: 1-2). The
FSMC motor score was significantly higher in MS patients
(23.1 ± 10.5) than in HC (14.8 ± 5.8; 𝑃 < 0.02). The FSMC
cognitive scores, cognitive performance, MSFC scores, and
anxiety and depression scores (HAD) were not significantly
different between groups (𝑃 > 0.1).
3.2. Contrasts Combinations and Lesion Combination Distri-
bution. We found 12 𝑧-scores combinations in all MS lesions
(1402 lesions, Figure 3). These combinations characterised
plaques with no significant contrast changes (Group 1: com-
bination 1, 54% cortical and 46% WM lesions), prevalent
inflammatory edema (Group 2: isolated increase of T2 and/or
T2∗𝑧-scores, combinations 2–4, 40% of cortical and 60%
of WM lesions), microdegeneration, and/or inflammatory
edema (Group 3: increase in T1 and/or increase in T2/T2∗,
combinations 5–8, 2% cortical and 98% WM lesions), and
broad tissue loss (Group 4: strong increase in T1 and decrease
in MTR 𝑧-scores, with or without increase in T2/T2∗,
combinations 9–12, 100%WM lesions) (Figure 3).
Most of the lesions (70%) showed a significantly high T1
𝑧-score (Group 3 and 4) and only 27% of total number of
lesions did not show any significant change in all contrasts
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Figure 4: Lesion groups distribution in RRMS patients. Groups 1
and 3 account for more than 60% of all lesions and are the most
represented groups in patients.
Table 1: Lesions count in brain hemispheres and cerebellum.
Combinations
Brain Cerebellum
WM Cortical WM Cortical
Type I Type II GM/WM GM
1 161 186 7 10 11 0
2 7 8 4 0 1 0
3 10 3 0 0 1 0
4 438 7 6 24 0 0
5 3 1 0 0 0 0
6 216 0 0 1 0 0
7 50 1 1 3 0 0
8 89 0 0 1 0 0
9 51 0 0 0 0 0
10 8 0 0 0 0 0
11 34 0 0 0 0 0
12 58 0 0 1 0 0
Total no. 1125 206 18 40 13 0
% 80.24 14.69 1.28 2.85 0.93 0
(Group 1); 48%of lesions showedhighT1 𝑧-score only (Group
3), 32% exhibited high T1 𝑧-score combined with high T2 or
T2∗ (Group 3), and 18%were characterized by highT1 𝑧-score
combined with low MTR (Group 4). Group 2 containing
lesions with high T2 and/or T2∗ and “nonsignificant” T1 and
MTR counted less than 3% of the total number of lesions
(Figure 4).
The cortical lesions represented 17% of the total number
of lesions; 90%were cortical lesions Type I (mixed GM/WM)
and 10% Type II (GM only) (Table 1). They mainly belong
to combination 1 (85%) and combinations 2 to 8. Most of
the lesions were pure white matter lesions (83%, Table 1) and
appeared in all combinations.
3.3. Multivariate Linear Regression of Clinical Scores in
Patients with T1, T2, and 𝑇2∗ and MTR in Lesions. GLM
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Table 2: Multiple regression analysis between lesion combinations, covariates, and clinical scores.
(a)
Predictors (𝑃 value) Clinical scores
MSFC FV SRT SDMT Tot10/36 FSMCCog FSMCMot
Stepwise regression
𝑃 value 0.00006∗ 0.00024∗ 0.00219# 0.00054∗ 0.03156† 0.03120† 0.03090†
Corrected 𝑃 value 0.00045∗ 0.00166# 0.01536† 0.00379# 0.22092‡ 0.21840‡ 0.21630‡
Adjusted-𝑅 0.55050 0.45350 0.38040 0.48960 0.20990 0.24770 0.2483
Cross-validation:
leave-one-out
𝑃 value 0.00001∗ 0.00004∗ 0.00097∗ 0.01300†
Corrected 𝑃 value 0.00005∗ 0.00030∗ 0.00677# 0.09100‡
Adjusted-𝑅 0.43660 0.37490 0.25620 0.14360
(b)
Predictors (𝑃 value) Clinical scores
MSFC FV SRT SDMT Tot10/36 FSMCCog FSMCMot
𝑧-scores combination
Group 1
Combination 1 0.0048# 0.0003∗
Group 2
Combination 2
Combination 3
Combination 4
Group 3
Combination 5 0.0003∗ 0.0088# 0.0223†
Combination 6 0.0182† 0.0049#
Combination 7
Combination 8 0.0200†
Group 4
Combination 9 0.0011# 0.0256† 0.0175† 0.0001∗ 0.0331† 0.0168†
Combination 10 0.0057#
Combination 11
Combination 12
Covariates
Age 0.0056# 0.0144†
Gender 0.0007∗ 0.0004∗
Educational years
HADA (anxiety) 0.0436†
HADD (depression) 0.0341† 0.0400† 0.0136†
∗P < 0.001.
#P < 0.01.
†P < 0.05.
Table 2(a): each line corresponds to the𝑃 values, corrected𝑃 values, and adjusted-𝑅of eachmodel (𝑛 = 7) subjected to regression and cross-validation analysis.
Table 2(b): each line corresponds to the P values of each predictor for every regression model performed.
The different symbols denote the difference in significance: ∗highest significance (𝑃 < 0.001), #middle range significance (𝑃 < 0.01), †low significance (𝑃 <
0.05), and ‡nonsignificant predictor (𝑃 > 0.05).
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using stepwise regression revealed a highly significant asso-
ciation, confirmed by a cross-validation test, between lesions
MRI characteristics of lesions and three clinical scores
(Table 2).
(i) The MLV in combinations 8 and 9 (Group 3 and 4)
together with age and depression score predicted the
MSFC (general disability) score (Adj-𝑅2 = 0.6; 𝑃 =
0.0005).
(ii) The MLV in combinations 5, 6, and 9 (Group 3
and 4) in conjunction with gender predicted the FV
(execution) score (Adj-𝑅2 = 0.5; 𝑃 = 0.002).
(iii) TheMLV in combinations 1, 9, and 10 (Groups 1 and 4)
predicted the SRT (verbal memory) score (Adj-𝑅2 =
0.4; 𝑃 = 0.002).
(iv) MLV in combinations 1, 5, 6 and 9 (Groups 1, 3, and
4) with age and depression score predicted the SDMT
(attention function) score (Adj-𝑅2 = 0.5; 𝑃 = 0.004).
Nevertheless, cross-validation test revealed a possible
overfitting of theGLM(estimated score versus clinical
score: Adj-𝑅2 = 0.1; 𝑃 = 0.09).
4. Discussion
Current diagnostic and prognostic criteria in MS as well
as clinical trials end-points are based on conventional MRI
measures of lesions number, volume, and activity [33]. Nev-
ertheless, these parameters provide only limited information
about the nature and severity of tissue alterations in the
central nervous system.
In fact, changes in conventional T1 and T2 signals
are compatible with both inflammatory and degenerative
phenomena [20]; moreover, the presence of “black holes,”
considered to be a marker of permanent axonal/myelin loss
[34, 35], might be also due to inflammatory extracellular
edema [35] and activated microglia [36, 37]. Furthermore,
gadolinium (Gd) enhancement, a conventional marker of
active inflammation, does not detect active lesions with
mild changes in blood-brain barrier (BBB) permeability [38]
and disseminated inflammation due to activated microglia
[39]. In addition, the presence of Gd uptake might reveal
incomplete restoration of tight junction integrity and BBB
function in inactive, noninflamed, chronic lesions [40].
We recently showed the potential of advanced MRI
techniques to unravel the nature of diffuse and focal tissue
pathology in MS [20]. In this work, we aimed at investigating
the influence of unconventionalMRImetrics of lesion pathol-
ogy on patients’ disability and cognition.
In accordance with previous literature at 3 T [11] we found
that themajority of lesions detected in our cohort of earlyMS
patients were located inWM (83%), amoderate number were
mixed WM/GM (cortical lesion Type I) (15%), and few were
purely cortical and punctiform (cortical lesion Type II) (2%)
(Table 1).
We identified twelve combinations of MRI contrasts in
MS lesions, which we organized into four main groups
according to the predominant underlying pathology (Fig-
ure 3). Group 1 was constituted by lesions that did not
show any significant contrast change, possibly due to patho-
physiological causes (i.e., presence of more efficient repar-
ative processes in early stages of disease) and/or technical
aspects (lack of sensitivity/spatial resolution). The other
three groups were constituted by lesions exhibiting prevalent
inflammation (Group 2), microdegeneration with/without
inflammation (Group 3), or predominant tissue loss (Group
4). These four groups were consistent with those reported by
the histopathological “Vienna Classification” of MS lesions
(Group 1: Vienna lesion type VLT 6; Group 2: VLT 2; Group
3: VLT 2/5; and Group 4: VLT 5) [41].
Interestingly, we did not observe any T1/T2/T2∗ decrease
in local plaques, suggesting that no significant iron accumu-
lation occurs in our cohort of patients. However, since we
performed an average lesion analysis, this observation does
not exclude the presence of local iron increase, as previously
reported [13, 42].
Last, we studied the relative impact of lesion combi-
nations/groups on clinical performance in patients. And
we found that lesions with concomitant microdegenera-
tion/inflammation or important tissue loss had a greater
impact on patients’ disability, executive function, and verbal
memory than prevalent inflammatory lesions. This result
could be due to the presence of a minority of lesions in
the purely inflammatory group (Group 2), which might be
due to the fact that most of the patients were benefitting
of immunomodulatory/immunodepressive therapy. In addi-
tion, lesions with no significant changes in multicontrast
MRI (Group 1) played an important role in verbal memory
and attention. This aspect is coherent with the fact that the
majority of Group 1 lesions were located in the cortical layers;
yet, it could be also due to the fact that a proportion ofGroup 1
lesions are located in eloquent areas. In order to elucidate this
last point, an ongoing study is aiming at integrating the lesion
location information in the current lesion classification.
In summary, our current work provides a new approach
to infer histopathological information from MS plaques and
supports evidence that MRI measures of lesion pathology are
strong determinants of patients’ clinical performance in our
cohort.
A technical limitation of this study is the low in-plane
resolution of the T2 relaxation maps, compared to the
other applied maps and MRI contrasts. Though we tried
to overcome this limit by setting a threshold to lesion size
(>10 voxels), this aspect could impact the estimations of
average T2 values in small lesions. Future hardware and
software improvements are required to achieve higher spa-
tial resolution in accelerated T2 relaxometry acquisitions.
Another limitation of this method is the lack of sensitivity
to repair/plasticity (i.e., gliosis, axonal remodeling, etc.) as
well as to other inflammatory phenomena like lympho-
cytic/microglia infiltration and activation. Studies focusing
on the longitudinal pattern of contrasts evolution in MS
lesions and the combination with other MRI contrasts (i.e.,
diffusion imaging) or modalities (i.e., MRI-PET) might help
to overcome these limits.
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